Literature DB >> 11414508

Lipid peroxidation and glutathione peroxidase activity in chronic obstructive pulmonary disease exacerbation: prognostic value of malondialdehyde.

U Sahin1, M Unlü, F Ozgüner, R Sütcü, A Akkaya, N Delibas.   

Abstract

Results of recent studies have indicated that during exacerbation of chronic obstructive pulmonary disease (COPD), antioxidant capacity is lower and the levels of lipid peroxidation products are higher than those in age-matched healthy subjects. The aim of this study was to assess the time course of changes in oxidant stress during the treatment of exacerbation of COPD. For this purpose, we measured erythrocyte glutathione peroxidase (GPx) activity and serum levels of the lipid peroxidation product malondialdehyde (MDA) in 18 male patients with acute exacerbation of COPD. Fifteen healthy non-smokers having no history of lung disease served as control subjects. Mean erythrocyte GPx values of patients were 45.54 +/- 9.04 u/gHb on admission and had increased to 72.77 +/- 9.68 by the tenth day of treatment, but still remained lower than those of healthy subjects (83.13 +/- 10.91) (p=0.007). Serum MDA values in patients were Vol. 12, No. 1, 2001 significantly higher (2.68 +/- 1.28 nmol/ml) than those in control subjects (1.04 +/- 0.36 nmol/ml) (p=0.000) and returned to normal values by the tenth day of treatment (1.08 +/- 0.36 nmol/ml) (p=0.766). Erythrocyte GPx values in patients who were current smokers (39.87 +/- 3.82 u/gHb) were lower than those in ex-smokers (49.15 +/- 9.67 u/gHb) (p=0.021). Moreover, serum MDA values in patients who were current smokers (3.32 +/- 1.18 nmol/ml) were higher than those in ex-smokers (1.66 +/- 0.60 nmol/ml) (p=0.007). The results show that oxidative stress in patients with acute exacerbation of COPD is related to higher MDA levels that return to normal conditions during the course of treatment. In conclusion, the results suggest that MDA levels can serve as a marker of prognosis and of the success of treatment of the exacerbation of COPD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414508     DOI: 10.1515/jbcpp.2001.12.1.59

Source DB:  PubMed          Journal:  J Basic Clin Physiol Pharmacol        ISSN: 0792-6855


  8 in total

1.  Oxidative stress in patients with COPD and pulmonary hypertension.

Authors:  Pavol Joppa; Darina Petrásová; Branislav Stancák; Zuzana Dorková; Ruzena Tkácová
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

Review 2.  Oxidative stress in COPD and its measurement through exhaled breath condensate.

Authors:  Wei Lee; Paul S Thomas
Journal:  Clin Transl Sci       Date:  2009-04       Impact factor: 4.689

Review 3.  Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review.

Authors:  You Xu; Hongmei Liu; Lei Song
Journal:  J Nanobiotechnology       Date:  2020-10-19       Impact factor: 10.435

4.  Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice.

Authors:  Thomas E Sussan; Tirumalai Rangasamy; David J Blake; Deepti Malhotra; Hazim El-Haddad; Djahida Bedja; Melinda S Yates; Ponvijay Kombairaju; Masayuki Yamamoto; Karen T Liby; Michael B Sporn; Kathleen L Gabrielson; Hunter C Champion; Rubin M Tuder; Thomas W Kensler; Shyam Biswal
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-22       Impact factor: 11.205

Review 5.  Oxidants and the pathogenesis of lung diseases.

Authors:  Jonathan Ciencewicki; Shweta Trivedi; Steven R Kleeberger
Journal:  J Allergy Clin Immunol       Date:  2008-09       Impact factor: 10.793

Review 6.  Inhaled RNA Therapeutics for Obstructive Airway Diseases: Recent Advances and Future Prospects.

Authors:  You Xu; Aneesh Thakur; Yibang Zhang; Camilla Foged
Journal:  Pharmaceutics       Date:  2021-01-28       Impact factor: 6.321

7.  Oxidant-antioxidant balance in the blood of patients with chronic obstructive pulmonary disease after smoking cessation.

Authors:  Alina Woźniak; Dariusz Górecki; Michał Szpinda; Celestyna Mila-Kierzenkowska; Bartosz Woźniak
Journal:  Oxid Med Cell Longev       Date:  2013-09-05       Impact factor: 6.543

8.  Malondialdehyde in dried blood spots: a biomarker of systemic lipid peroxidation linked to cardiopulmonary symptoms and risk factors.

Authors:  Yan Lin; Xiangtian Wang; Luciane Lenz; Ousmane Ndiaye; Jian Qin; Xiaoli Wang; Hui Huang; Marc A Jeuland; Junfeng Jim Zhang
Journal:  J Thorac Dis       Date:  2021-06       Impact factor: 2.895

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.